Retatrutide is a synthetic, modified incretin-receptor research peptide associated with GLP-1, GIP and glucagon receptor signalling research. Laboratory work involving retatrutide commonly examines multi-receptor peptide design, acylated peptide stability and metabolic receptor pathway models.
Retatrutide is a synthetic, modified incretin-receptor research peptide associated with GLP-1, GIP and glucagon receptor signalling research. Laboratory work involving retatrutide commonly examines multi-receptor peptide design, acylated peptide stability and metabolic receptor pathway models. This material should be presented strictly as a qualified laboratory research compound and not as a medical product.
The following information is provided for research-catalogue and product specification purposes only. Batch-specific identity, purity, salt form and analytical values should be confirmed against the relevant Certificate of Analysis.
| What it is | Retatrutide is a synthetic, modified incretin-receptor research peptide associated with GLP-1, GIP and glucagon receptor signalling research. Laboratory work involving retatrutide commonly examines multi-receptor peptide design, acylated peptide stability and metabolic receptor pathway models. This material should be presented strictly as a qualified laboratory research compound and not as a medical product. |
|---|---|
| Sequence | Modified long-chain acylated peptide; full modified sequence is COA-specific and should be verified against supplier analytical data |
| Molecular weight | 4731.42 g/mol |
| Product family | Incretin receptor peptide analogue |
| Research classification | Synthetic multi-receptor peptide analogue; GLP-1/GIP/glucagon signalling research compound |
| Form | Lyophilised powder |
| Appearance | White to off-white powder |
| Fill quantity | 10mg |
| Container type | Sterile sealed glass vial |
| Storage | Store dry, protected from light at -20°C. Avoid repeated freeze/thaw cycles after reconstitution. |
| Synonyms | Retatrutide; LY3437943; Triple-G receptor agonist research peptide |
| CAS number | 2381089-83-2 |
| Molecular form / formula | C221H342N46O68 |
| Molecule form | Modified acylated peptide; salt form COA-specific |
| Purity | Recommended product standard: >=98% by HPLC; confirm by batch COA |
| Analysis method | HPLC and LC-MS / MS confirmation |
Each compound is accompanied by third-party analytical documentation where available. Certificates confirm purity, identity and chromatographic analysis against the supplied batch.
Orders are typically processed within 1–2 business days of confirmed payment. Estimated delivery is 10–21 business days after dispatch, depending on destination and courier coverage. All shipping is tracked and discreetly packaged.
Store dry, protected from light at -20°C. Avoid repeated freeze/thaw cycles after reconstitution.
| Form | Lyophilised powder |
|---|---|
| Appearance | White to off-white powder |
| Container type | Sterile sealed glass vial |
| Storage & Handling | Store dry, protected from light at -20°C. Avoid repeated freeze/thaw cycles after reconstitution. |
All products are supplied by Greek Peptides for research use only. They are not licensed as pharmaceuticals and are not promoted as, or intended to diagnose, treat, cure, prevent or mitigate any disease or medical condition in humans or animals. They are not intended for human or animal consumption and are not intended for cosmetic, nutritional or recreational use.
By purchasing, the purchaser confirms that they are a qualified individual acting for legitimate research purposes only and accepts our Terms and Conditions and Research Use Policy.
